::Asahi Kasei Pharma America:: Art 123 / Advisory Board






Naoki Aikawa, MD, DMSc, FACS Gordon R. Bernard, MD Mark Crowther, MD Charles Esmon, PhD Jawed Fareed, PhD, DSC, FACB Kenneth J. Gorelick, MD, Chairman Marcel Levi, MD, PhD Howard Levy, MD, PhD, MMM Joseph E. Parrillo, MD Jean-Louis Vincent, MD ART 123 Program Advisory Board Asahi Kasei Pharma America has recruited a team of some of the most renowned experts in sepsis, critical care and hematology specifically to help guide the development and commercialization of ART 123. Charles Esmon, PhD Dr. Esmon has major research interests revolving around the interactions and mutual regulation of blood coagulation and inflammation. His research involves the protein C anticoagulant pathway and the impact of perturbations of this pathway on the acute inflammatory response such as occurs in severe sepsis. Dr. Esmon and Dr. Fletcher Taylor collaborated to become the first investigators to show that activated protein C could prevent and treat a normally lethal septic response in animals. Meanwhile, Dr. Esmon and Dr. Whyte Owen collaborated to become the first investigators to identify thrombomodulin. Subsequent work from their laboratories led to the isolation and characterization of thrombomodulin. In addition, Dr. Esmon and Dr. Kenji Fukudome identified, cloned and characterized the endothelial cell protein C receptor that serves as a cofactor for thrombomodulin-mediated protein C activation. Dr. Esmon is a member of the National Academy of Science, an Investigator for the Howard Hughes Medical Institute, and the Head of the Cardiovascular Biology Research Program at the Oklahoma Medical Research Foundation. He has more than 300 publications related to the above areas and has served as a consultant with a number of large and small pharmaceutical companies.

Home Profile Management Board of Directors Art 123 Advisory Board

ART 123 Program Advisory Board

Asahi Kasei Pharma America has recruited a team of some of the most renowned experts in sepsis, critical care and hematology specifically to help guide the development and commercialization of ART 123.